How India Exports Olaparib to the World

The U.S. Food and Drug Administration (FDA) initially approved olaparib capsules in December 2014 for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who had been treated with three or more prior lines of chemotherapy. Subsequently, in August 2017, the FDA granted regular approval to olaparib tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. In December 2018, the FDA expanded the indication to include the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for olaparib, indicating the absence of generic competition in the U.S. market. This exclusivity underscores the importance of understanding the regulatory pathways and market dynamics for potential exporters. The absence of import alerts related to olaparib suggests compliance with FDA standards by current manufacturers.

The European Medicines Agency (EMA) granted marketing authorization for olaparib (Lynparza) on December 16, 2014, for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. (ema.europa.eu) In September 2022, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved olaparib for the adjuvant treatment of high-risk early-stage breast cancer with inherited BRCA mutations. (icr.ac.uk)

The EMA has also provided product-specific bioequivalence guidance for olaparib, effective from January 1, 2023, outlining the requirements for demonstrating bioequivalence in generic formulations. (ema.europa.eu) Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers exporting to the European Union and the UK.

As of March 2026, olaparib is not listed on the World Health Organization's (WHO) Model List of Essential Medicines. Consequently, it has not undergone WHO Prequalification. However, olaparib's inclusion in major pharmacopoeias such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) ensures standardized quality specifications for its production and quality control.

In India, olaparib is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO) and the National Pharmaceutical Pricing Authority (NPPA) have not set a ceiling price for olaparib as of March 2026, allowing manufacturers to determine pricing. For export purposes, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) is mandatory, ensuring compliance with national regulations.

Olaparib's primary patents are held by AstraZeneca, with the main patent expected to expire in December 2028. This patent protection currently limits the entry of generic versions into the market. However, the absence of approved ANDAs in the FDA's Orange Book suggests that generic competition may emerge post-patent expiration, potentially impacting market dynamics.

In March 2022, the FDA approved olaparib for the adjuvant treatment of high-risk early-stage breast cancer with inherited BRCA mutations, expanding its therapeutic indications. In September 2022, the MHRA granted approval for the same indication in the UK, aligning with the FDA's decision. (icr.ac.uk)

In June 2022, the EMA adopted product-specific bioequivalence guidance for olaparib, effective from January 1, 2023, providing a framework for the development of generic formulations. (ema.europa.eu) These developments reflect the evolving regulatory landscape and the potential for increased market competition in the coming years.

Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor used in oncology, relies on a complex synthesis process involving multiple key starting materials (KSMs) and intermediates. India, a significant producer of active pharmaceutical ingredients (APIs), often depends on imports for these critical raw materials. Notably, China controls approximately 70–80% of the global KSM supply and 60–70% of intermediates, making it a dominant player in the upstream pharmaceutical supply chain. This heavy reliance on Chinese imports exposes Indian manufacturers to potential supply disruptions.

Historical instances underscore this vulnerability. For example, in July 2018, environmental regulations led to the shutdown of several Chinese chemical plants, causing significant supply shortages and price increases for KSMs and intermediates. These disruptions had a cascading effect on global API production, including in India, highlighting the risks associated with concentrated sourcing.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Olaparib account for 72.9% of total export value, with BDR Pharmaceuticals International Private Limited leading at 31.0%. This high supplier concentration poses a significant risk; any operational or regulatory issues affecting these key players could disrupt the entire supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme for pharmaceuticals, aiming to bolster domestic manufacturing and reduce import dependence. As of March 2025, the scheme has led to the creation of domestic manufacturing capacity for 25 identified KSMs, APIs, and drug intermediates, resulting in import savings of ₹1,362 crore. However, the effectiveness of the PLI scheme in diversifying Olaparib's supplier base remains to be fully realized.

Global shipping routes, particularly the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical raw materials and finished products. Geopolitical tensions in these regions can lead to shipping delays and increased costs. Additionally, ongoing US-China trade tensions have the potential to disrupt the supply of KSMs and intermediates sourced from China, further impacting the pharmaceutical supply chain.

Regulatory bodies such as the FDA and EMA have previously issued alerts regarding drug shortages resulting from supply chain disruptions. For instance, in 2024, the FDA highlighted shortages of certain oncology drugs due to manufacturing delays and increased demand, underscoring the fragility of the supply chain.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Olaparib and its raw materials to reduce dependence on a limited number of exporters.

• Enhance Domestic Production: Leverage the PLI scheme to incentivize domestic manufacturing of KSMs and intermediates essential for Olaparib production.

• Strengthen Supply Chain Monitoring: Implement robust monitoring systems to detect early signs of supply disruptions and enable proactive responses.

• Develop Strategic Reserves: Establish reserves of critical raw materials to buffer against short-term supply interruptions.

• Foster International Collaboration: Engage in partnerships with other countries to develop a more resilient and diversified global supply chain for pharmaceutical ingredients.

RISK_LEVEL: MEDIUM